Opthea Limited
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Opthea Limited sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Opthea Limited: 5 sponsored US clinical trials, none currently recruiting.
Opthea Limited sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 2 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetic Macular Edema, with 1 trials.
Upper-quartile sponsor footprint
Opthea Limited sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
NCT04757610
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)
NCT04757636
A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema
NCT03397264
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
NCT03345082
Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD
NCT02543229
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 2 |
Therapeutic Areas
How the Opthea Limited archive is shaped
5 indexed studies, none listed as recruiting (0% open); 3 completed (60%).
Phase mix: 2 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Diabetic Macular Edema (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Opthea Limited: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Opthea Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Opthea Limited page
5 registered trials is a research-attention snapshot, not an endorsement of Opthea Limited or any single study.
- None of Opthea Limited's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Diabetic Macular Edema is the condition Opthea Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetic Macular Edema trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Opthea Limited pipeline card: 5 registered trials from official public datasets.Report a data error.